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disease. Patient demographic factors, tumor characteristics and treat-
ment delivered were examined. Kaplan-Meier survival curves were 
calculated to estimate survival rates. Cox proportional hazards ratios 
were used to identify independent prognostic factors for survival. 
Results: Advanced age at diagnosis, male sex, low socioeconomic 
status (SES), non-surgical treatment, and poor histologic grade (stage 
IA NSCLC: hazard ratio [HR] = 1.14; 95% conﬁdence interval [CI]: 
1.08 - 1.19; stage IB NSCLC: HR = 1.11; 95% CI: 1.07 - 1.16) were 
associated with increased mortality risk on multivariate analysis. 
Non-upper lobar tumor location (right middle lobe, right and left lower 
lobes) and tumor size ≥ 4 cm (vs. < 4 cm; HR = 1.22; 95% CI = 1.15-
1.30) were additional factors with increased mortality risk among stage 
IB patients. Bronchioloalveolar carcinoma and Asian ethnicity were 
associated with decreased mortality risk in stage I NSCLC.
Conclusions: Stage I NSCLC with poorly-differentiated histology and 
stage IB NSCLC with non-upper lobar tumor location or tumor size ≥ 4 
cm carried increased mortality risk. 
A=well-diﬀerentiated, B=moderately-diﬀerentiated, C=poorly-diﬀerenti-
ated, D=undiﬀerentiated
A=upper lobar tumor location, B=non-upper lobar tumor location
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Background: Gene ampliﬁcation is a cellular process characterized 
by selective increase in the copy numbers of a DNA segment including 
one or more genes. The phenomenon ampliﬁes the phenotype conferred 
by these genes and is known to be a major source for overexpression 
of oncogenes in cancer. In addition, ampliﬁed and overexpressed genes 
have been targeted in developmental therapeutic approaches, improving 
survival and reducing side effects of treatment. In NSCLC, EGFR is an 
example of these two situations: gene ampliﬁcation associates with pro-
tein overexpression and anti-EGFR approaches have been developed 
as antibodies and small molecules (TKI) that inhibit the tyrosine kinase 
domain of the gene. This study investigated the patterns of EGFR gene 
ampliﬁcation detected in NSCLC and their association with sensitivity 
to TKIs.
Methods: Dual-color FISH assays with LSI SO EGFR/SG CEP 7 (Vy-
sis/Abbott Molecular) were performed in tumors from 1225 NSCLC 
patients treated with geﬁtinib or erlotinib. EGFR gene ampliﬁcation 
was detected in 102 specimens (8.3%) and molecular patterns were rec-
ognized. Outcome to treatment included response according to RECIST 
criteria, time to progression and overall survival.
Results: Ampliﬁed genomic segments were manifested as two rec-
ognizable forms: homogeneously staining regions (HSR), which are 
repeated genomic regions located intra-chromosomally, were found in 
100 (98%) tumors; and double minute chromosomes (DM), which are 
extra-chromosomal segments of ampliﬁed DNA, were found. in two 
cases. Among the HSC cases, 47 tumors had a large number of EGFR 
copies per cluster (10 to >50) while 25 had a smaller number (4 to >10 
copies per cluster). In all these cases the signals were loosely arranged. 
In 12 tumors, the clusters comprised very tightly arranged signals, mak-
ing the enumeration practically impossible. In 9 tumors, the EGFR sig-
nals had an abnormally large and bright presentation although multiple 
spots were not visible. Another clustered pattern consisted of co-local-
ization of EGFR and CEP 7 signals, in which the number of repeats 
were high (4 tumors) or low (3 tumors). In these cases, sequences of 
CEP 7 were either included in the amplicon or interspaced with EGFR 
sequences. The distribution of EGFR-ampliﬁed cells in the tumor 
section was restricted to some foci in 18% of cases, and was diffusely 
spread throughout the entire specimen in 82% of cases. 
Conclusions: Patterns of EGFR gene ampliﬁcation in NSCLC are 
complex and heterogeneous. Accurate laboratorial diagnosis is critical 
for applicability of this phenomenon as a marker to select patients for 
therapy with EGFR TKIs. Correlation of the distinct patterns of EGFR 
gene ampliﬁcation with sensitivity to TKIs is ongoing and will be 
presented at the meeting.
